Safety Study of Gene Therapy for Ischemic Heart Disease in Korea

Phase 1/2 Completed 9 enrolled Helixmith Co., Ltd.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety of VM202 (Engensis) direct injection into the cardiac muscles of the coronary artery territory where complete revascularization could not be done even through Coronary Artery Bypass Graft (CABG).

Timeline

Start: 2007-01
Primary completion: 2010-02
Completion: 2014-08

Publications

Background Kim JS, Hwang HY, Cho KR, Park EA, Lee W, Paeng JC, Lee DS, Kim HK, Sohn DW, Kim KB. Intramyocardial transfer of hepatocyte growth factor as an adjunct to CABG: phase I clinical study. Gene Ther. 2013 Jul;20(7):717-22. doi: 10.1038/gt.2012.87. Epub 2012 Nov 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VM202	Other / unclassified	0.5 mg	Other
Subject	VM202	Other / unclassified	1 mg	Other
Subject	VM202	Other / unclassified	2 mg	Other

Safety Study of Gene Therapy for Ischemic Heart Disease in Korea

Summary

Timeline

Publications

Drugs

Indications